Axinn Obtains Denial of a TRO Motion for Client Zydus
April 23, 2015
Axinn attorneys succeeded in obtaining a denial of a TRO motion that had sought an order to keep Axinn client Zydus from marketing its generic version of Abilify (aripiprazole). Abilify is a multi-billion dollar drug marketed by Otsuka, and Otsuka sought a ruling from the United States District Court for the District of New Jersey that the marketing of Zydus’ generic aripiprazole product would infringe Otsuka’s patent. The Axinn team included Jason Murata. Additionally, the firm was joined by a number of other defendants in opposing Otsuka’s TRO motion.
To subscribe to our publications, click here.
Featured Insights
Featured Insights
CCWC 21st Annual Career Strategies Conference
Speaking Engagement
SCCE 23rd Annual Compliance & Ethics Institute
Speaking Engagement
Antitrust
HNBA/VIA Annual Convention 2025
Sponsorship
Antitrust
Key Appellate Decisions Shaping Antitrust Strategy
Webinar
Antitrust
ACI 12th Annual Summit for Women Leaders in Life Sciences Law
Speaking Engagement
Intellectual Property
National LGBTQ+ Bar Association Lavender Law Conference and Career Fair 2025
Sponsorship
National Bar Association 100th Annual Convention and Exhibits
Sponsorship
Antitrust
Axinn Attorneys Named to the 2025 Lawdragon 500 X – The Next Generation Guide
Awards & Recognitions
Keeping Pace: Updates in Cartel Enforcement
Webinar
Antitrust
Hanging in the Balance: Supreme Court Declines to Decide the Uninjured Class Member Question in Labcorp v. Davis
Axinn Viewpoints
Antitrust